TW200637546A - Combination therapy - Google Patents

Combination therapy

Info

Publication number
TW200637546A
TW200637546A TW094144909A TW94144909A TW200637546A TW 200637546 A TW200637546 A TW 200637546A TW 094144909 A TW094144909 A TW 094144909A TW 94144909 A TW94144909 A TW 94144909A TW 200637546 A TW200637546 A TW 200637546A
Authority
TW
Taiwan
Prior art keywords
hydrochlorothiazide
combination therapy
telmisartan
angiotensin
treatment
Prior art date
Application number
TW094144909A
Other languages
English (en)
Chinese (zh)
Inventor
Helmut E Schumacher
Axel Riedel
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200637546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200637546A publication Critical patent/TW200637546A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
TW094144909A 2004-12-17 2005-12-16 Combination therapy TW200637546A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
TW200637546A true TW200637546A (en) 2006-11-01

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144909A TW200637546A (en) 2004-12-17 2005-12-16 Combination therapy

Country Status (15)

Country Link
EP (1) EP1827424A1 (enExample)
JP (1) JP2008524136A (enExample)
KR (1) KR20070097511A (enExample)
CN (1) CN101080225A (enExample)
AR (1) AR052052A1 (enExample)
AU (1) AU2005315855A1 (enExample)
BR (1) BRPI0519656A2 (enExample)
CA (1) CA2589493A1 (enExample)
EA (1) EA200701159A1 (enExample)
IL (1) IL183944A0 (enExample)
NO (1) NO20072325L (enExample)
PE (1) PE20060768A1 (enExample)
TW (1) TW200637546A (enExample)
UY (1) UY29274A1 (enExample)
WO (1) WO2006063737A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
RU2465916C2 (ru) * 2007-10-19 2012-11-10 Оцука Фармасьютикал Ко., Лтд. Твердый фармацевтический препарат матричного типа
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2252273B1 (en) 2008-03-19 2016-12-28 ratiopharm GmbH Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
WO2010013835A2 (en) * 2008-07-31 2010-02-04 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002423A2 (en) * 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE
JP6422868B2 (ja) 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
ES2445041T3 (es) * 2002-01-16 2014-02-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Método para la preparación de telmisartán amorfo

Also Published As

Publication number Publication date
JP2008524136A (ja) 2008-07-10
PE20060768A1 (es) 2006-09-29
BRPI0519656A2 (pt) 2009-03-03
IL183944A0 (en) 2007-10-31
AU2005315855A1 (en) 2006-06-22
AR052052A1 (es) 2007-02-28
UY29274A1 (es) 2006-07-31
CA2589493A1 (en) 2006-06-22
WO2006063737A1 (en) 2006-06-22
CN101080225A (zh) 2007-11-28
EP1827424A1 (en) 2007-09-05
KR20070097511A (ko) 2007-10-04
NO20072325L (no) 2007-07-06
EA200701159A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
TW200637546A (en) Combination therapy
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
WO2004010975A3 (en) Controlled drug delivery
EP2335727A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MY137620A (en) Therapeutic treatment
WO2009134056A3 (ko) 약제학적 제제
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
WO2008064138A3 (en) Personalized therapeutic treatment process
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
WO2006030030A3 (de) System zur sequentiellen, transdermalen verabreichung von systemisch wirksamen substanzen
TH83710A (th) การบำบัดรวม
WO2004087132A8 (en) Combination drug therapy for treating hypertension
UA69994A (en) Method for correcting nephropathy in hypertension patients
WO2005011589A3 (en) Drug delivery methods and devices
RU2004134447A (ru) Применение препарата "мексикор" (2-этил-6-метил-3-оксипиридина сукцината) для лечения нефритов и нефропатий
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante